ACER (MC $29 M ) Covid 19 DATA this Q + 2x Phase 3 assets

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ACER (MC $29 M ) Covid 19 DATA this Q + 2x Phase 3 assets

An SI Board Since December 2020

Posts	SubjectMarks	Bans	Symbol
1	1	0	ACER

Emcee: BioHero	Type: Moderated

Introduction Market Data Compact

Data from Covid 19 program expected any day now this could push this low float stock toward $10 fast . One of the CHEAÜEST biotechs on Nasdaq .

Market Cap $29 Million /Shares Out 12.3 Million / 2x Phase 3 Assets / 2x NDA (Re)submission expected during next 6-9 months / readout from Covid 19 trial expected during this month if positive Company wil start Phase 2/3 in 1H 2021 / Strong Insider & Institutional Ownership = Low float stock with MASSIVE Upside Potential which could hit $20 and more on Drug approvals and positive results (more infos below) .GL

Acer Therapeutics (ACER)

Market Cap : $29 Million

Cash $7 Million

Price $2.40

Shares Out 12.3 Million

Latest Presentation
acertx.com

These 2 Penny Stocks Are Poised for a Massive Rally, Says Roth Capital..
finance.yahoo.com

Go to reply# or date (mm/dd/yy):